Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy (J Clin Neurol, 2022, 18, (5), 547-552, 10.3988/jcn.2022.18.5.547)

Se Hee Kim; Han Som Choi; Chung Mo Koo; Bong Rim Joo; Byung Joo Park; Hae Kook Lee; Joon Soo Lee; Heung Dong Kim; Hoon Chul Kang

doi:10.3988/jcn.2022.18.5.547e

Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy (J Clin Neurol, 2022, 18, (5), 547-552, 10.3988/jcn.2022.18.5.547)

Se Hee Kim, Han Som Choi, Chung Mo Koo, Bong Rim Joo, Byung Joo Park, Hae Kook Lee, Joon Soo Lee, Heung Dong Kim, Hoon Chul Kang

Department of Pediatrics

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

We would like to revise the contents of the methods as below. CBD was prescribed on the first visit when screening was performed. An oral pharmaceutical formulation of highly purified CBD (100 mg/mL; Epidiolex, GW Research, Cambridge, United Kingdom) was used. The starting dosage of CBD ranged between 2.5-5 mg/kg/day, which was titrated to 10 mg/kg/day after 2 weeks. If a patient continued to have seizures, the dose could be increased up to 20 mg/kg/day. (figure presented).

Original language	English
Pages (from-to)	214
Number of pages	1
Journal	Journal of Clinical Neurology (Korea)
Volume	19
Issue number	2
DOIs	https://doi.org/10.3988/jcn.2022.18.5.547e
Publication status	Published - 2023

Bibliographical note

Publisher Copyright:
© 2023 Korean Neurological Association.

All Science Journal Classification (ASJC) codes

Neurology
Clinical Neurology

Access to Document

10.3988/jcn.2022.18.5.547e

Cite this

Kim, S. H., Choi, H. S., Koo, C. M., Joo, B. R., Park, B. J., Lee, H. K., Lee, J. S., Kim, H. D., & Kang, H. C. (2023). Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy (J Clin Neurol, 2022, 18, (5), 547-552, 10.3988/jcn.2022.18.5.547). Journal of Clinical Neurology (Korea), 19(2), 214. https://doi.org/10.3988/jcn.2022.18.5.547e

@article{89284198940241d7a03be86b89c58c8e,

title = "Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy (J Clin Neurol, 2022, 18, (5), 547-552, 10.3988/jcn.2022.18.5.547)",

abstract = "We would like to revise the contents of the methods as below. CBD was prescribed on the first visit when screening was performed. An oral pharmaceutical formulation of highly purified CBD (100 mg/mL; Epidiolex, GW Research, Cambridge, United Kingdom) was used. The starting dosage of CBD ranged between 2.5-5 mg/kg/day, which was titrated to 10 mg/kg/day after 2 weeks. If a patient continued to have seizures, the dose could be increased up to 20 mg/kg/day. (figure presented).",

author = "Kim, {Se Hee} and Choi, {Han Som} and Koo, {Chung Mo} and Joo, {Bong Rim} and Park, {Byung Joo} and Lee, {Hae Kook} and Lee, {Joon Soo} and Kim, {Heung Dong} and Kang, {Hoon Chul}",

note = "Publisher Copyright: {\textcopyright} 2023 Korean Neurological Association.",

year = "2023",

doi = "10.3988/jcn.2022.18.5.547e",

language = "English",

volume = "19",

pages = "214",

journal = "Journal of Clinical Neurology (Korea)",

issn = "1738-6586",

publisher = "Korean Neurological Association",

number = "2",

}

Kim, SH, Choi, HS, Koo, CM, Joo, BR, Park, BJ, Lee, HK, Lee, JS, Kim, HD & Kang, HC 2023, 'Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy (J Clin Neurol, 2022, 18, (5), 547-552, 10.3988/jcn.2022.18.5.547)', Journal of Clinical Neurology (Korea), vol. 19, no. 2, pp. 214. https://doi.org/10.3988/jcn.2022.18.5.547e

Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy (J Clin Neurol, 2022, 18, (5), 547-552, 10.3988/jcn.2022.18.5.547). / Kim, Se Hee; Choi, Han Som; Koo, Chung Mo et al.
In: Journal of Clinical Neurology (Korea), Vol. 19, No. 2, 2023, p. 214.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Erratum

T2 - Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy (J Clin Neurol, 2022, 18, (5), 547-552, 10.3988/jcn.2022.18.5.547)

AU - Kim, Se Hee

AU - Choi, Han Som

AU - Koo, Chung Mo

AU - Joo, Bong Rim

AU - Park, Byung Joo

AU - Lee, Hae Kook

AU - Lee, Joon Soo

AU - Kim, Heung Dong

AU - Kang, Hoon Chul

PY - 2023

Y1 - 2023

N2 - We would like to revise the contents of the methods as below. CBD was prescribed on the first visit when screening was performed. An oral pharmaceutical formulation of highly purified CBD (100 mg/mL; Epidiolex, GW Research, Cambridge, United Kingdom) was used. The starting dosage of CBD ranged between 2.5-5 mg/kg/day, which was titrated to 10 mg/kg/day after 2 weeks. If a patient continued to have seizures, the dose could be increased up to 20 mg/kg/day. (figure presented).

AB - We would like to revise the contents of the methods as below. CBD was prescribed on the first visit when screening was performed. An oral pharmaceutical formulation of highly purified CBD (100 mg/mL; Epidiolex, GW Research, Cambridge, United Kingdom) was used. The starting dosage of CBD ranged between 2.5-5 mg/kg/day, which was titrated to 10 mg/kg/day after 2 weeks. If a patient continued to have seizures, the dose could be increased up to 20 mg/kg/day. (figure presented).

UR - http://www.scopus.com/inward/record.url?scp=85149437946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149437946&partnerID=8YFLogxK

U2 - 10.3988/jcn.2022.18.5.547e

DO - 10.3988/jcn.2022.18.5.547e

M3 - Comment/debate

AN - SCOPUS:85149437946

SN - 1738-6586

VL - 19

SP - 214

JO - Journal of Clinical Neurology (Korea)

JF - Journal of Clinical Neurology (Korea)

IS - 2

ER -

Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy (J Clin Neurol, 2022, 18, (5), 547-552, 10.3988/jcn.2022.18.5.547)

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this